{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126493","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.620775+00:00","generated_at":"2026-05-15T08:53:36.763107+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"BridgeBio Oncology appoints Peter Lebowitz as independent director; NCG, Compensation committees; option grant","bullets":["Board size increased to nine; Lebowitz appointed as Class I director.","Lebowitz is independent and serves on NCG and Compensation committees.","Received one-time option for 63,350 shares at $8.72/share (closing price on 3/24/2026).","Standard indemnification agreement executed covering expenses from board service.","No disclosable transactions under Reg S-K Item 404(a) involving Lebowitz."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126493","json":"https://secwatch.observer/filing/0001193125-26-126493.json","markdown":"https://secwatch.observer/filing/0001193125-26-126493.md","text":"https://secwatch.observer/filing/0001193125-26-126493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/0001193125-26-126493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/d126641d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:53:36.763107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}